POLYETHYLENE GLYCOL

Polyethylene Glycol Adverse Events Reported to the FDA Over Time

How are Polyethylene Glycol adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Polyethylene Glycol, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Polyethylene Glycol is flagged as the suspect drug causing the adverse event.

Most Common Polyethylene Glycol Adverse Events Reported to the FDA

What are the most common Polyethylene Glycol adverse events reported to the FDA?

Death	82 (2.69%)
Diarrhoea	47 (1.54%)
Haemoglobin Decreased	45 (1.48%)
Pyrexia	40 (1.31%)
Vomiting	34 (1.12%)
Atrial Fibrillation	32 (1.05%)
Dyspnoea	32 (1.05%)
Pneumonia	31 (1.02%)
Cerebrovascular Accident	30 (.99%)
Acute Myocardial Infarction	27 (.89%)
Peripheral Arterial Occlusive Disea...	27 (.89%)
	Show More
Arteriovenous Fistula Thrombosis	26 (.85%)
Colitis Ischaemic	26 (.85%)
Drug Ineffective	26 (.85%)
Dysgeusia	25 (.82%)
Ischaemic Stroke	25 (.82%)
Sepsis	25 (.82%)
Gastroenteritis	24 (.79%)
Hypotension	23 (.76%)
Femoral Artery Occlusion	22 (.72%)
Nausea	22 (.72%)
Myocardial Infarction	21 (.69%)
Pulmonary Embolism	21 (.69%)
Abdominal Pain	19 (.62%)
Incorrect Drug Administration Durat...	19 (.62%)
Chest Pain	18 (.59%)
Convulsion	18 (.59%)
Hyponatraemia	17 (.56%)
Renal Failure Chronic	17 (.56%)
Renal Impairment	17 (.56%)
Angina Pectoris	16 (.53%)
Carotid Artery Stenosis	16 (.53%)
Overdose	16 (.53%)
Pruritus	16 (.53%)
Thrombosis	16 (.53%)
Abdominal Distension	15 (.49%)
Anaemia	15 (.49%)
Gastrointestinal Haemorrhage	15 (.49%)
Thrombocytopenia	15 (.49%)
Cardiac Failure	14 (.46%)
Hypersensitivity	14 (.46%)
Hypertension	14 (.46%)
Platelet Count Decreased	14 (.46%)
Pleural Effusion	14 (.46%)
Rash	14 (.46%)
Asthenia	13 (.43%)
Bacterial Infection	13 (.43%)
Device Malfunction	13 (.43%)
Pulmonary Oedema	13 (.43%)
Upper Gastrointestinal Haemorrhage	13 (.43%)
Urticaria	13 (.43%)
Bile Duct Cancer	12 (.39%)
Cellulitis	12 (.39%)
Diverticulum Intestinal	12 (.39%)
Fall	12 (.39%)
Oedema Peripheral	12 (.39%)
Tremor	12 (.39%)
Abdominal Pain Upper	11 (.36%)
Constipation	11 (.36%)
Dehydration	11 (.36%)
Dizziness	11 (.36%)
Ill-defined Disorder	11 (.36%)
Lymphangitis	11 (.36%)
Optic Ischaemic Neuropathy	11 (.36%)
Pancytopenia	11 (.36%)
Renal Failure Acute	11 (.36%)
Back Pain	10 (.33%)
Cardio-respiratory Arrest	10 (.33%)
Diarrhoea Infectious	10 (.33%)
Drug Interaction	10 (.33%)
Haemorrhage	10 (.33%)
Haemorrhagic Anaemia	10 (.33%)
Headache	10 (.33%)
Malaise	10 (.33%)
Oesophagitis	10 (.33%)
Off Label Use	10 (.33%)
Pseudomembranous Colitis	10 (.33%)
Rectal Haemorrhage	10 (.33%)
Spinal Osteoarthritis	10 (.33%)
Sudden Death	10 (.33%)
Arrhythmia	9 (.3%)
Arthralgia	9 (.3%)
Blood Potassium Increased	9 (.3%)
Cardiac Arrest	9 (.3%)
Confusional State	9 (.3%)
Drug Effect Decreased	9 (.3%)
Extremity Necrosis	9 (.3%)
Inappropriate Schedule Of Drug Admi...	9 (.3%)
Lung Neoplasm Malignant	9 (.3%)
Urinary Tract Infection	9 (.3%)
Angina Unstable	8 (.26%)
Bradycardia	8 (.26%)
Cardiac Failure Congestive	8 (.26%)
Chronic Myeloid Leukaemia	8 (.26%)
Condition Aggravated	8 (.26%)
Drug Hypersensitivity	8 (.26%)
Gastrointestinal Necrosis	8 (.26%)
Hyperkalaemia	8 (.26%)
Hypoglycaemia	8 (.26%)
Hypokalaemia	8 (.26%)
Intestinal Ischaemia	8 (.26%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Polyethylene Glycol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Polyethylene Glycol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Polyethylene Glycol

What are the most common Polyethylene Glycol adverse events reported to the FDA?

Infections - Pathogen Unspecified	180 (5.91%)
Gastrointestinal Signs	137 (4.5%)
Cardiac Arrhythmias	100 (3.28%)
Neurological	100 (3.28%)
Fatal Outcomes	92 (3.02%)
Coronary Artery	88 (2.89%)
Procedural And Device Related Injur...	87 (2.86%)
Central Nervous System Vascular	85 (2.79%)
Hematology Investigations	82 (2.69%)
Respiratory	76 (2.5%)
Epidermal And Dermal Conditions	73 (2.4%)
	Show More
Bacterial Infectious	71 (2.33%)
Arteriosclerosis, Stenosis, Vascula...	69 (2.27%)
Electrolyte And Fluid Balance Condi...	68 (2.23%)
Medication Errors	67 (2.2%)
Gastrointestinal Motility And Defec...	65 (2.13%)
Gastrointestinal Hemorrhages	59 (1.94%)
Renal Disorders	55 (1.81%)
Therapeutic And Nontherapeutic Effe...	55 (1.81%)
Body Temperature Conditions	49 (1.61%)
Anemias Nonhemolytic And Marrow Dep...	46 (1.51%)
Injuries	43 (1.41%)
Gastrointestinal Inflammatory Condi...	39 (1.28%)
Allergic Conditions	36 (1.18%)
Heart Failures	32 (1.05%)
Decreased And Nonspecific Blood Pre...	31 (1.02%)
Pulmonary Vascular	26 (.85%)
Hepatic And Hepatobiliary	25 (.82%)
Joint	24 (.79%)
Ocular Infections, Irritations And ...	24 (.79%)
Gastrointestinal Vascular Condition...	23 (.76%)
Lower Respiratory Tract Disorders	23 (.76%)
Gastrointestinal Ulceration And Per...	22 (.72%)
Seizures	22 (.72%)
Water, Electrolyte And Mineral	22 (.72%)
Cardiac And Vascular Investigations	19 (.62%)
Embolism And Thrombosis	19 (.62%)
Vascular Hypertensive	19 (.62%)
Angiedema And Urticaria	18 (.59%)
Hepatobiliary Neoplasms Malignant A...	17 (.56%)
Movement Disorders	17 (.56%)
Musculoskeletal And Connective Tiss...	17 (.56%)
Eye	16 (.53%)
Leukemias	16 (.53%)
Vision	16 (.53%)
Platelet	15 (.49%)
Product Quality Issues	15 (.49%)
Deliria	14 (.46%)
Gastrointestinal Stenosis And Obstr...	14 (.46%)
Pleural	14 (.46%)
Respiratory And Mediastinal Neoplas...	14 (.46%)
Therapeutic Procedures And Supporti...	13 (.43%)
Vascular	13 (.43%)
Vascular Hemorrhagic	13 (.43%)
Diverticular	12 (.39%)
Headaches	12 (.39%)
Muscle	12 (.39%)
Ocular Hemorrhages And Vascular	12 (.39%)
Urinary Tract Signs	12 (.39%)
Coagulopathies And Bleeding Diathes...	11 (.36%)
Fungal Infectious	11 (.36%)
Oral Soft Tissue Conditions	11 (.36%)
Glucose Metabolism Disorders	10 (.33%)
Immunology And Allergy	10 (.33%)
White Blood Cell	10 (.33%)
Anxiety Disorders	9 (.3%)
Bone And Joint Injuries	9 (.3%)
Gastrointestinal	9 (.3%)
Gastrointestinal Neoplasms Malignan...	9 (.3%)
Pericardial	9 (.3%)
Peritoneal And Retroperitoneal Cond...	9 (.3%)
Physical Examination Topics	9 (.3%)
Acid-base	8 (.26%)
Exocrine Pancreas Conditions	8 (.26%)
Hemolyses And Related Conditions	8 (.26%)
Lymphomas Non-hodgkins B-cell	8 (.26%)
Bone Disorders	7 (.23%)
Bronchial Disorders	7 (.23%)
Cardiac Valve	7 (.23%)
Increased Intracranial Pressure And...	7 (.23%)
Inner Ear And Viiith Cranial Nerve	7 (.23%)
Metabolic, Nutritional And Blood Ga...	7 (.23%)
Skin And Subcutaneous Tissue Disord...	7 (.23%)
Tongue Conditions	7 (.23%)
Upper Respiratory Tract Disorders	7 (.23%)
Viral Infectious	7 (.23%)
Abdominal Hernias And Other Abdomin...	6 (.2%)
Chemical Injury And Poisoning	6 (.2%)
Mental Impairment	6 (.2%)
Myocardial	6 (.2%)
Plasma Cell Neoplasms	6 (.2%)
Renal And Urinary Tract Investigati...	6 (.2%)
Suicidal And Self-injurious Behavio...	6 (.2%)
Anal And Rectal Conditions	5 (.16%)
Breast Neoplasms Malignant And Unsp...	5 (.16%)
Cardiac Disorder Signs	5 (.16%)
Gastrointestinal Conditions	5 (.16%)
Hepatobiliary	5 (.16%)
Neoplasm Related Morbidities	5 (.16%)
Appetite And General Nutritional	4 (.13%)
Endocrine Investigations	4 (.13%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Polyethylene Glycol, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Polyethylene Glycol is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.